Bristol Myers Squibb (NYSE: BMY) strengthens Camzyos growth case with positive adolescent SCOUT-HCM data
Read More Pharma Industry News Merck launches Phase 3 CORALreef program for PCSK9 inhibitor MK-0616 Pharmaceutical giant Merck has announced the initiation of its groundbreaking Phase 3 clinical program, CORALreef, focusing on MK-0616—a… byPallavi MadhirajuAugust 25, 2023